Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer

BACKGROUND: Trastuzumab-induced cardiotoxicity (TIC) can lead to early discontinuation of adjuvant therapy, however there is limited evidence on long-term survival outcomes in patients with operable human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) experiencing treatment in...

Descripción completa

Detalles Bibliográficos
Autores principales: Sardesai, Sagar, Sukumar, Jasmine, Kassem, Mahmoud, Palettas, Marilly, Stephens, Julie, Morgan, Evan, Addison, Daniel, Baliga, Ragavendra, Stover, Daniel G., VanDeusen, Jeffrey, Williams, Nicole, Cherian, Mathew, Lustberg, Maryam, Wesolowski, Robert, Ramaswamy, Bhuvaneswari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643282/
https://www.ncbi.nlm.nih.gov/pubmed/33292843
http://dx.doi.org/10.1186/s40959-020-00081-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643282/
https://www.ncbi.nlm.nih.gov/pubmed/33292843
http://dx.doi.org/10.1186/s40959-020-00081-9

Ejemplares similares